Atezolizumab plus cobimetinib improves PFS in biliary tract cancer

Atezolizumab plus cobimetinib significantly prolonged PFS compared with atezolizumab alone among a cohort of patients with advanced biliary tract cancer, according to results of a phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.The combination also demonstrated manageable toxicity in what researchers described as the first randomized trial of immunotherapy in this patient population.“Biliary tract cancers are uncommon cancers, accounting for approximately 3% of all gastrointestinal malignancies. However, incidence is increasing, which mayRead More

Share on facebook
Share on twitter
Share on linkedin